Search

Abrocitinib

Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). … [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.

Crizanlizumab

It was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug

Pyrophosphoric acid

Spectinomycin

An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

Beremagene geperpavec

Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

Zanidatamab

[A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

Danaparoid

The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. … Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT).

Fosnetupitant

In April 2018, the U.S. … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].

Aurothioglucose

Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326].

Obinutuzumab

[L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis. … This chemical modification significantly enhances its affinity for FcγRIII receptors on immune effector cells.